Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [203Pb]Pb-PSV359
Pb-PSV359 · 1 trial · 8 indications
Incidence and severity of treatment-related adverse events following a single administration of \[203Pb\]Pb-PSV359 is determined
Incidence and severity of treatment-related adverse events following a single and each repeated administration of \[212Pb\]Pb-PSV359 is determined
The recommended phase 2 dose as determined by cohort observations and review by the Safety Monitoring Committee
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | * Enrolled subjects are administered \[203Pb\]Pb-PSV359 (7mCi) for imaging FAP-expressing cancers. * Approximately Four cohorts of \[212Pb\]Pb-PSV359 dose levels will be explored for determining Recommended Phase 2 Dose (RP2D). Study subjects will be assigned to cohorts sequentially. |
| Dose Expansion | EXPERIMENTAL | * Enrolled subjects are administered \[203Pb\]Pb-PSV359 (7mCi) for imaging FAP-expressing cancers. * Enrolled subjects are administered \[212Pb\]Pb-PSV359 (RP2D determined previously) for treatment of FAP-expressing cancers |
| Name | Type | Description |
|---|---|---|
| [203Pb]Pb-PSV359 | DRUG | \[203Pb\]Pb-PSV359 is administered by intravenous bolus injection for single-photon emission computed tomography imaging. |
| [212Pb]Pb-PSV359 | DRUG | \[212Pb\]Pb-PSV359 is administered by intravenous infusion for treatment of FAP expressing cancers. |
Inclusion Criteria: * Aged ≥ 18 years * Satisfactory organ function as determined by laboratory testing * Eastern Cooperative Oncology Group performance (ECOG) status of 0 to 1 * Life expectancy \> 3 months * Progressive disease despite standard therapy or for whom no standard therapy exists * Posi...
Pb-PSV359 is an investigational small molecule being developed for the treatment of pancreatic ductal adenocarcinoma, as well as other solid tumors including gastric, esophageal, colorectal, ovarian, head and neck cancers, sarcoma, and mesothelioma. It is currently in Phase 1 clinical development.
Pb-PSV359 is a small molecule that delivers lead-212, a radioactive isotope, to tumor cells. It is designed to target solid tumors and is being studied for its therapeutic effects in multiple cancer types, including pancreatic ductal adenocarcinoma.
Pb-PSV359 is being developed by Perspective Therapeutics, Inc., a company traded on the NYSE American under the ticker symbol CATX. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy.
Pb-PSV359 is in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to assess its safety, dosing, and preliminary efficacy in patients with solid tumors.
Pb-PSV359 is being studied in a Phase 1 clinical trial with the identifier NCT06710756. This trial, titled 'Lead-212 PSV359 Therapy for Patients With Solid Tumors,' is recruiting participants in the United States and has a target enrollment of 112 patients.
Yes, Pb-PSV359 is also known as [203Pb]Pb-PSV359. The compound is being investigated for its therapeutic potential in solid tumors, and the alternative name reflects the lead-203 isotope used in imaging or diagnostic applications of the same molecule.